Skip to main content
Simcere Pharmaceutical Group Limited logo

Simcere Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · S2P ISIN · HK0000658531 HKEX Manufacturing
Open in API
Filings indexed 577 across all filing types
Latest filing 2020-10-13 Capital/Financing Update
Country CN China
Listing HKEX S2P

About Simcere Pharmaceutical Group Limited

https://www.simcere.com/en/

Simcere Pharmaceutical Group Limited is an R&D-driven pharmaceutical company specializing in the discovery, development, and commercialization of innovative and branded generic prescription drugs. The company strategically focuses on core therapeutic areas, including neuroscience, anti-oncology, and inflammatory diseases. Simcere emphasizes synergistic innovation, evidenced by its development and launch of multiple Category I innovative pharmaceuticals and its strategic collaborations with global partners to advance novel treatments. These partnerships aim to address significant unmet medical needs and expand the company's portfolio across specialized disease areas.

Recent filings

Filing Released Lang Actions
GLOBAL OFFERING
Capital/Financing Update Classification · 95% confidence The document is a table of contents and navigation page for a 'Global Offering' prospectus for Simcere Pharmaceutical Group Limited. It lists various sections typical of an IPO prospectus, such as 'Industry Overview', 'Financial Information', 'Underwriting', and 'Accountants' Report'. Since this is the primary document used for a public offering of shares, it falls under the category of a prospectus, which is classified as 'POS' (or in this specific taxonomy, 'SHA' for share issuance/capital change or 'RNS' as a regulatory filing, but given the specific nature of a Global Offering prospectus, it is best categorized as a regulatory filing related to share issuance). However, looking at the provided codes, 'SHA' is the most appropriate fit for a document detailing a Global Offering/Share Issue.
2020-10-13 English
GLOBAL OFFERING
Capital/Financing Update Classification · 100% confidence The document is titled 'GLOBAL OFFERING' and contains detailed information about the number of shares offered, offer price, underwriting, expected timetable for application and allocation, and disclaimers about the offering. It is a prospectus related to a public offering of shares by Simcere Pharmaceutical Group Limited. The content focuses on the offering of shares, pricing, application procedures, and regulatory disclaimers typical of an IPO or share issuance prospectus. This matches the characteristics of a Capital/Financing Update, which covers company fundraising and capital structure changes. It is not an annual report, earnings release, or other report types. The document length is substantial and contains detailed offering information, not just an announcement or summary, so it is not a Report Publication Announcement or Regulatory Filing. Therefore, the appropriate classification is Capital/Financing Update (CAP).
2020-10-13 English
GLOBAL OFFERING
Capital/Financing Update Classification · 95% confidence The document is an announcement related to a Global Offering by Simcere Pharmaceutical Group Limited, detailing the number of shares offered, offer price, underwriting arrangements, application procedures, and listing information. It references the Prospectus dated October 13, 2020, and provides extensive information about the public offering and share allocation. The content is typical of a capital raising event announcement, specifically an initial public offering (IPO) or share issuance. There is no indication that this is a full annual report, earnings release, or other financial report. The document is not a proxy statement, nor a voting result announcement, nor a management or audit report. It is clearly an update on capital raising and share issuance activities. Therefore, the most appropriate classification is Capital/Financing Update (CAP). The document length (15,000 characters) and detailed content support this classification with high confidence.
2020-10-13 English
PHIP (1st submission)
Regulatory Filings Classification · 95% confidence The document is a 'PHIP' (Preliminary Hearing Information Document) from the Hong Kong Stock Exchange (HKEX). PHIPs are preliminary versions of a prospectus used for IPOs. Since the document provides a list of links to sections of a prospectus (e.g., Business, Financial Information, Accountants' Report) and is an announcement of the availability of these materials for an upcoming listing, it functions as a Report Publication Announcement (RPA) regarding the IPO prospectus.
2020-10-06 English
PHIP (1st submission)
Regulatory Filings Classification · 95% confidence The document is titled 'Post Hearing Information Pack' (PHIP) and is issued by Simcere Pharmaceutical Group Limited. It is explicitly stated to be a draft, incomplete, and subject to change. The document includes warnings that it is not a prospectus or an offer to sell securities, and it is related to a public offering application process. The text references the Stock Exchange of Hong Kong Limited and the Securities and Futures Commission, indicating regulatory compliance context. The document contains sections such as 'Expected Timetable', 'Risk Factors', 'Industry Overview', and 'Corporate Information', which are typical components of a listing or offering document but not a final prospectus. The document is not a full financial report, earnings release, or management discussion but rather an informational pack related to a listing or offering process. Given the nature of the document as a draft information pack required by the exchange and commission for public information purposes, and the emphasis on it not being a final prospectus or offer document, this fits the category of a Regulatory Filing (RNS) as it is a regulatory announcement providing information but not the final report or prospectus itself.
2020-10-06 English
Application Proof (1st submission)
Audit Report / Information Classification · 95% confidence The document is an 'Application Proof' for Simcere Pharmaceutical Group Limited, which is a standard term used in the Hong Kong Stock Exchange (HKEX) listing process for an initial public offering (IPO). The structure of the document, including sections like 'Industry Overview', 'Financial Information', 'Underwriting', and 'Accountants' Report', confirms it is a prospectus or a pre-listing disclosure document. Since the provided categories do not include a specific 'IPO Prospectus' code, and it is a regulatory filing related to a capital market event, 'RNS' (Regulatory Filings) is the most appropriate fallback category. FY 2020
2020-06-10 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.